Abstract
Background and Aim: Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. The aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation.Methods: Data on 153 patients were reviewed. The study population was classified into three groups: 73 (47.8%) patients who received neither angiotensin‐converting enzyme inhibitors nor sartans (group 1), 49 (32%) patients treated with angiotensin‐converting enzyme inhibitors (group 2), and 31 (20.2%) patients treated with sartans (group 3). Survival outcomes were analysed by means of Kaplan–Meier analysis and compared with log–rank test.Results: In the whole study population, 85.6% of patients were in Child–Pugh A class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30 mm (10–40) and alpha fetoprotein was 25 (1.1–2100) UI/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (95% confidence interval: 31–58) in group 1, 72 months (49–89) in group 2, and 84 months (58–92) in group 3 (P = 0.02). Median time to recurrence was 26 (15–42), 44 (33–72), and 69 (44–74) months in the three groups, respectively (P = 0.02). Sartan therapy was a significant predictor of longer overall survival and delayed time to recurrence on multivariate analysis.Conclusion: Sartans significantly improved overall survival and time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients.